11 December 2020 : Original article
Outcomes of Non-Cryopreserved Versus Cryopreserved Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma
Pokpong Piriyakhuntorn1ABCDE*, Adisak Tantiworawit1AE, Thanawat Rattanathammethee1E, Sasinee Hantrakool1E, Chatree Chai-Adisaksopha1E, Ekarat Rattarittamrong1E, Lalita Norasetthada1EDOI: 10.12659/AOT.927084
Ann Transplant 2020; 25:e927084
Table 1 Baseline patient demography and clinical characteristics.
Characteristics | Non-cryopreserved (N=26) | Cryopreserved (N=16) | P-value |
---|---|---|---|
Age (year) – mean±SD | 55.7±5.2 | 54.9±5.9 | 0.685 |
Male – no. (%) | 11 (42.3) | 8 (50.0) | 0.627 |
ISS stage – no. (%) | 0.688 | ||
I | 8 (30.8) | 3 (18.8) | |
II | 10 (38.5) | 7 (43.8) | |
III | 8 (30.8) | 6 (37.5) | |
First ASCT – no. (%) | 26 (100) | 10 (62.5) | 0.002 |
Induction regimen – no. (%) | 0.073 | ||
Bor-Cy-Dex | 23 (88.5) | 12 (75.0) | |
Bor-Dex | 3 (11.5) | 0 | |
Bor-Len-Dex | 0 | 1 (6.3) | |
Len-Cy-Dex | 0 | 2 (12.5) | |
Len-Dex | 0 | 1 (6.3) | |
Total cycles of induction – median (IQR) | 5.5 (4–6) | 6 (6–8) | 0.140 |
Disease response before ASCT – no. (%) | 0.904 | ||
sCR | 12 (46.2) | 9 (56.3) | |
CR | 3 (11.5) | 2 (12.5) | |
VGPR | 6 (23.1) | 3 (18.8) | |
PR | 5 (19.2) | 2 (12.5) | |
HCT-CI – no. (%) | 0.231 | ||
0 | 15 (57.7) | 13 (81.3) | |
1–2 | 9 (34.6) | 3 (18.8) | |
3 | 2 (7.7) | 0 | |
Mobilization regimen – no. (%) | 0.005 | ||
G-CSF | 26 (100) | 11 (68.8) | |
G-CSF + Cy | 0 | 5 (31.2) | |
Conditioning regimen – no. (%) | 0.180 | ||
Melphalan 200 mg/m | 24 (92.3) | 12 (75.0) | |
Melphalan 140 mg/m | 2 (7.7) | 4 (25.0) | |
ASCT – autologous stem cell transplantation; Bor – bortezomib; CR – complete response; Cy – cyclophosphamide; Dex – dexamethasone; G-CSF – granulocyte colony stimulating factor; HCT-CI – hematopoietic cell transplantation-specific comorbidity index; ISS – International Staging System; Len – lenalidomide; PR – partial response; sCR – stringent complete response; VGPR – very good partial response. |